Logo image of MSPR

MSP RECOVERY INC (MSPR) Stock Fundamental Analysis

NASDAQ:MSPR - Nasdaq - US5537453087 - Common Stock - Currency: USD

1.32  +0.08 (+6.45%)

Premarket: 1.38 +0.06 (+4.55%)

Fundamental Rating

2

MSPR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of MSPR have multiple concerns. MSPR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MSPR had negative earnings in the past year.
In the past year MSPR has reported a negative cash flow from operations.
In the past 5 years MSPR always reported negative net income.
MSPR had negative operating cash flow in 4 of the past 5 years.
MSPR Yearly Net Income VS EBIT VS OCF VS FCFMSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

MSPR's Return On Assets of -25.77% is on the low side compared to the rest of the industry. MSPR is outperformed by 85.44% of its industry peers.
Industry RankSector Rank
ROA -25.77%
ROE N/A
ROIC N/A
ROA(3y)-6.93%
ROA(5y)-37.77%
ROE(3y)-128.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MSPR Yearly ROA, ROE, ROICMSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Gross Margin of MSPR (33.20%) is better than 63.11% of its industry peers.
MSPR's Gross Margin has declined in the last couple of years.
MSPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.71%
GM growth 5YN/A
MSPR Yearly Profit, Operating, Gross MarginsMSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

MSPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MSPR has been reduced compared to 1 year ago.
Compared to 5 years ago, MSPR has less shares outstanding
MSPR has a worse debt/assets ratio than last year.
MSPR Yearly Shares OutstandingMSPR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1B 2B 3B
MSPR Yearly Total Debt VS Total AssetsMSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of -1.72, we must say that MSPR is in the distress zone and has some risk of bankruptcy.
MSPR has a Altman-Z score of -1.72. This is amonst the worse of the industry: MSPR underperforms 84.47% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.72
ROIC/WACCN/A
WACC0.38%
MSPR Yearly LT Debt VS Equity VS FCFMSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 0.02 indicates that MSPR may have some problems paying its short term obligations.
MSPR's Current ratio of 0.02 is on the low side compared to the rest of the industry. MSPR is outperformed by 95.15% of its industry peers.
MSPR has a Quick Ratio of 0.02. This is a bad value and indicates that MSPR is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.02, MSPR is not doing good in the industry: 95.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
MSPR Yearly Current Assets VS Current LiabilitesMSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

MSPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -626.43%.
Looking at the last year, MSPR shows a very strong growth in Revenue. The Revenue has grown by 34.77%.
Measured over the past years, MSPR shows a small growth in Revenue. The Revenue has been growing by 7.65% on average per year.
EPS 1Y (TTM)-626.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.19%
Revenue 1Y (TTM)34.77%
Revenue growth 3Y7.65%
Revenue growth 5YN/A
Sales Q2Q%-86.05%

3.2 Future

Based on estimates for the next years, MSPR will show a very strong growth in Earnings Per Share. The EPS will grow by 147.54% on average per year.
The Revenue is expected to grow by 145.11% on average over the next years. This is a very strong growth
EPS Next Y145.1%
EPS Next 2Y147.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year197.69%
Revenue Next 2Y145.11%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MSPR Yearly Revenue VS EstimatesMSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 10B 20B 30B 40B
MSPR Yearly EPS VS EstimatesMSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 200 400 600 800 1K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MSPR. In the last year negative earnings were reported.
MSPR is valuated cheaply with a Price/Forward Earnings ratio of 0.01.
Based on the Price/Forward Earnings ratio, MSPR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
MSPR is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.46, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.01
MSPR Price Earnings VS Forward Price EarningsMSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MSPR Per share dataMSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 -200

4.3 Compensation for Growth

MSPR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MSPR's earnings are expected to grow with 147.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y147.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MSPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MSP RECOVERY INC

NASDAQ:MSPR (6/24/2025, 8:00:00 PM)

Premarket: 1.38 +0.06 (+4.55%)

1.32

+0.08 (+6.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-15 2025-05-15
Earnings (Next)08-12 2025-08-12
Inst Owners6.42%
Inst Owner Change0%
Ins Owners26.2%
Ins Owner Change0%
Market Cap10.88M
Analysts82.86
Price TargetN/A
Short Float %7.73%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.01
P/S 0.83
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-263.65
EYN/A
EPS(NY)191.19
Fwd EY14483.9%
FCF(TTM)-2.9
FCFYN/A
OCF(TTM)-2.57
OCFYN/A
SpS1.59
BVpS-7.38
TBVpS-223.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.2%
FCFM N/A
ROA(3y)-6.93%
ROA(5y)-37.77%
ROE(3y)-128.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.71%
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.57%
Cap/Sales 20.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -1.72
F-Score2
WACC0.38%
ROIC/WACCN/A
Cap/Depr(3y)1.07%
Cap/Depr(5y)43.68%
Cap/Sales(3y)23.63%
Cap/Sales(5y)15.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-626.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.19%
EPS Next Y145.1%
EPS Next 2Y147.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)34.77%
Revenue growth 3Y7.65%
Revenue growth 5YN/A
Sales Q2Q%-86.05%
Revenue Next Year197.69%
Revenue Next 2Y145.11%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.43%
OCF growth 3YN/A
OCF growth 5YN/A